WhiteLab Genomics Series B (2026)
WhiteLab Genomics raised $26 million (€23 million) in a Series B round, announced on 2026-10-06. The round was led by AVP.
- Company
- WhiteLab Genomics
- Round type
- Series B
- Date
- 2026-10-06
- Amount
- $26M
- Industry
- biotechnology, AI platform for genomic medicines
- Location
- Paris, France
Summary
WhiteLab Genomics raised $26 million (€23 million) in Series B financing, reported on 2026-10-06. AVP led the round, joined by new investors Yaday Health and Blast Club and existing shareholders Omnes Capital and Debiopharm Innovation Fund. The financing will expand experimental validation of its AI-designed gene delivery technologies.
Investors
Lead
- AVP lead
Participating
- Yaday Health participant
- Blast Club participant
- Omnes Capital participant
- Debiopharm Innovation Fund participant
Sources
Last verified:
- https://european-biotechnology.com/latest-news/whitelab-secures-26m-to-expand-ai-designed-gene-delivery-assets/
Type: reputable publication. Accessed 2026-10-06.
European Biotechnology article dated 2026-10-06. Reports $26 million (€23 million) in Series B financing led by AVP, with new investors Yaday Health and Blast Club and existing shareholders Omnes Capital and Debiopharm Innovation Fund. - https://www.finsmes.com/2026/10/whitelab-genomics-raises-26m-in-series-b-funding.html
Type: reputable publication. Accessed 2026-10-06.
FinSMEs article dated 2026-10-06. Source of the Paris, France location. Its body says $26M, while its headline says $25M. It names the existing investors as Omnes and Debiopharm.